JYNT vs LH
JYNT: A chiropractic clinic franchisor pivoting to a capital-light franchised model to scale affordable, direct-pay wellness care across North America. LH: A global diagnostics and drug development laboratory leader that performs 750+ million clinical tests annually and supports 85% of new FDA-approved drugs through comprehensive testing capabilities.
Side-by-side fundamentals
| Metric | JYNT | LH | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $8.57 | $301.17 | |
| Market cap as of 2026-07-29 | $122M | $25.8B | |
| P/E as of 2026-07-29 | 38.83 | 26.69 | LH lower |
| PEG as of 2026-07-29 | n/a | 2.76 | |
| Net margin as of 2026-07-29 | +5.7% | +6.7% | LH higher |
| Gross margin as of 2026-07-29 | +80.6% | +28.8% | JYNT higher |
| Operating margin as of 2026-07-29 | +1.1% | +10.2% | LH higher |
| ROE as of 2026-07-29 | +16.9% | +10.9% | JYNT higher |
| ROA as of 2026-07-29 | +5.0% | +5.1% | LH higher |
| Debt / equity as of 2026-07-29 | 0.00 | 0.73 | JYNT lower |
| Revenue growth (YoY) as of 2026-07-29 | -70.6% | +7.3% | LH higher |
| Revenue CAGR (3y) SEC XBRL | +26.1% | +5.6% | JYNT higher |
| Dividend yield as of 2026-07-29 | n/a | +1.0% | |
| Dividend streak (yrs) SEC XBRL | n/a | 4 | |
| Beta as of 2026-07-29 | 1.04 | 0.86 | |
| 1-year return as of 2026-07-27 close | -24.6% | +13.7% | LH higher |
Fundamentals: Finnhub, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.